Know Cancer

or
forgot password

Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial


Phase 4
N/A
6 Years
Open (Enrolling)
Male
Hemophilia A

Thank you

Trial Information

Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial


Patients meeting the enrollment criteria will be consecutively enrolled at each
participating centre, randomized to be treated exclusively with a single FVIII product
either plasma-derived or recombinant, and followed up until inhibitor development or until
50 exposure days (EDs) or 3 years from enrolment have elapsed, whichever comes first. Study
products, belonging to the class of rFVIII concentrates and to the class of plasma-derived
VWF/FVIII concentrates, will be provided for free to the patients for all the duration of
the study


Inclusion Criteria:



- Male subjects

- Any ethnicity

- Age <6 years

- Severe haemophilia A (FVIII:C <1%), as confirmed at enrolment by the central
laboratory.

o Those patients diagnosed locally as severe but subsequently found to have FVIII
levels >= 1% on testing at the central laboratory will be separately recorded in the
screening list.

- Previously untreated (0 EDs to any FVIII concentrates or blood products) or minimally
treated (<5 EDs) with blood components, namely whole blood, fresh frozen plasma,
packed red blood cells, platelets or cryoprecipitate.

o Patients not meeting these criteria will be separately recorded in the screening
list.

- Negative inhibitor measurement at both local and central laboratory at screening

- Ability to comply with study requirements

- Signed informed consent of legal tutors o Patients who will not accept to enter into
the study or to be randomized will be separately recorded.

Exclusion Criteria:

- Previous history of FVIII inhibitor

- Other congenital or acquired bleeding defects

- Plasma FVIII level >= 1%, as assayed at the central laboratory

o Those patients originally diagnosed locally as severe but subsequently found to
have FVIII levels ranging from 1% to 2% on testing at the central laboratory will be
separately recorded in the screening list.

- Concomitant congenital or acquired immunodeficiency

- Concomitant treatment with systemic immunosuppressive drugs

- Concomitant treatment with any investigational drug

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

Frequency of FVIII inhibitor formation in patients treated with plasma-derived vWF/FVIII compared to patients treated with recombinant FVIII

Outcome Time Frame:

During the first 50 exposure days or first 3 years of enrollment, whichever occurs first

Safety Issue:

Yes

Principal Investigator

Pier M. Mannucci, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Milan, Milan, Italy

Authority:

Austria : Federal Ministry for Labour, Health, and Social Affairs

Study ID:

ABB - 09 - 001

NCT ID:

NCT01064284

Start Date:

November 2009

Completion Date:

November 2014

Related Keywords:

  • Hemophilia A
  • Hemophilia A
  • Factor VIII inhibitors
  • vWF/FVIII
  • rFVIII
  • Hemophilia A

Name

Location

Rush University Medical Center Chicago, Illinois  60612-3824
Childrens Hospital Los Angeles Los Angeles, California  90027
City of Hope Medical Center Duarte, California  91010
University of Illinois College of Medicine Chicago, Illinois  60612
Cook Children's Medical Center Fort Worth, Texas  76104
Mountain States Regional Hemophilia and Thrombosis Center Aurora, Colorado  80045
Childrens Hospital of Orange County Orange, California  92868-3874
Tulane University School of Medicine, Section of Hematology/Oncology New Orleans, Louisiana  70112
MSU Center for Bleeding and Clotting Disorders East Lansing, Michigan  48824
Univ of Mississippi Medical Center, Pediatric Hematology/Oncology Jackson, Mississippi  39216
Children's Mercy Hospital, Kansas City Regional Hemophilia Center Kansas City, Missouri  64108
Hemophilia Treatment Center of Las Vegas Las Vegas, Nevada  89109
University of New Mexico, Dept. of Pediatrics Albuquerque, New Mexico  87131
Sanford Health Hospital, Pediatric Hematology/Oncology Dept. Fargo, North Dakota  58102
The Childrens Hospital of Philadelphia Philadelphia, Pennsylvania  19104
Children's Medical Center, Center for Cancer and Blood Disorders Dallas, Texas  75235